Please login to the form below

Not currently logged in
Email:
Password:

Bayer moves vilaprisan into phase III trials for uterine fibroids

ASTEROID study will investigate safety and efficacy of the novel drug

Bayer

Bayer is beginning late-stage trials of vilaprisan, its novel oral, selective progesterone receptor modulator (SPRM) treatment for women with uterine fibroids.

The three-year, phase III ASTEROID study will investigate the efficacy and safety of 2mg of vilaprisan in patients with symptomatic uterine fibroids, and aims to recruit more than 3,600 patients in 900 centres across 40 countries.

Uterine fibroids are the most common benign gynecological tumors, with approximately 5-10% of women requiring treatment for the disease.

Efficacy measures will be assessed within the trial programme including the effect on heavy menstrual bleeding, reduction in fibroid size and improvement in quality of life.

Dr Joerg Moeller, member of the executive committee of Bayer AG’s pharmaceutical division and head of development, said the work would build on a phase II study of vilaprisan that had delivered “promising results”.

“It is our ambitious goal that our research efforts in this field result in a medical therapy that control symptoms and thereby significantly improves the quality of life for women with uterine fibroids,” he added.

Meanwhile, Allergan and Gedeon Richter plan to file their uterine fibroid drug ulipristal acetate in the US by the end of the year and Astellas is also busy in this area, have acquired Ogeda and its phase IIa candidate Fezolinetant.

Article by
Gemma Jones

7th July 2017

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics